MedPath

A Modified Platform Trial of Multiple CAMPs for the Management of Diabetic Foot Ulcers and Venous Leg Ulcers

Not Applicable
Recruiting
Conditions
Venous Leg Ulcer
Diabetic Foot Ulcer
Registration Number
NCT06453187
Lead Sponsor
Integra LifeSciences Corporation
Brief Summary

The purpose of this study is to determine how well multiple CAMPs (Cellular, Acellular and Matrix-Like Products) and Standard of Care work when compared to Standard of Care alone in achieving complete closure of hard-to-heal diabetic foot and venous leg ulcers.

Detailed Description

Hard to heal Chronic wounds affect a significant percentage of patients over their lifetime. For example, diabetic foot ulcers (DFU) are a major health complication that affect up to 15% of individuals with diabetes mellitus over their lifetime. The treatment of hard to heal chronic wounds is extremely challenging as ulcers such as DFUs and Venous Leg Ulcers (VLUs) may not respond to standard of care (SC) treatment and frequently become infected.

Advanced wound products like CAMPs have become an important strategy in the treatment of hard-to-heal chronic wounds by trapping and binding the patients' own cells to rebuild the dermis layer of the skin to aid in healing.

The study will evaluate the clinical utility of Multiple CAMPs in the closure of hard to heal diabetic foot ulcers and venous leg ulcers in subjects in comparison to Standard of Care treatment.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
350
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Percentage of complete wound closure for target ulcer1-12 weeks

The percentage of target ulcers, DFU and VLU, achieving complete wound closure Complete wound closure is defined as 100% re-epithelialization of the ulcer surface without detectable exudate

Secondary Outcome Measures
NameTimeMethod
Time to complete wound closure for target ulcer1-12 weeks

Time to closure will be determined for each treatment group and compared to SOC

Percentage of wound area reduction for target ulcer1-12 weeks

Percent Area Reduction (PAR) will be calculated from measurements at Week 1 compared to measurements at week 12

Adverse Events1-14 weeks

Incidence of adverse events will be evaluated weekly from the first study visit to the Closure Confirmation Visit (CCV).

Changes to pain associated with the target ulcer1-14 weeks

Change in target ulcer pain assessed weekly from the first study visit to the Closure Confirmation Visit (CCV), using a 0 to 10 Pain scale with 0 = "No Pain" and 10 = "Most Intense Pain Imaginable".

Determine improvement in Quality of Life1-14 weeks

Quality of Life assessed at the study randomization visit and the Closure Confirmation Visit (CCV), using a Minimal Important Difference (MID) of 0.50 based on the averaged overall score from 0 to 4 of all items the Wound Quality of Life (wQOL) checklist, with higher score indicating worse wQOL

Improvement of the Forgotten Wound Score (FWS)1-14 weeks

Forgotten Wound Score (FWS) assessed at the study randomization visit and the Closure Confirmation Visit (CCV) based a 0 to 100 scale with higher indicating a high degree of "forgetting" the wound

Trial Locations

Locations (12)

Center for Clinical Research

🇺🇸

San Francisco, California, United States

Medstar Washington Hospital Center (MWHC)

🇺🇸

Washington D.C., District of Columbia, United States

Barry University Clinical Research

🇺🇸

Tamarac, Florida, United States

Comprehensive Wound Healing Center, Northwell Health

🇺🇸

Lake Success, New York, United States

Phase One Clinical Trials, Inc.

🇺🇸

Bakersfield, California, United States

Angel City Research

🇺🇸

Los Angeles, California, United States

Symphony Research

🇺🇸

Jacksonville, Florida, United States

Denali Health Plant City, LLC

🇺🇸

Plant City, Florida, United States

Health Goods Management, LLC

🇺🇸

Winter Park, Florida, United States

Midwest Foot and Ankle Clinics

🇺🇸

Hoffman Estates, Illinois, United States

Scroll for more (2 remaining)
Center for Clinical Research
🇺🇸San Francisco, California, United States
Maria Peralta
Contact
800-363-1069
maria@ccr-trials.com
Reyzelman Alexander, DPM
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.